A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis
Status:
Completed
Trial end date:
2016-02-03
Target enrollment:
Participant gender:
Summary
This was a randomized, double blind, placebo controlled, parallel group study in
approximately 90 subjects with moderate-severe AD Eczema Area and Severity Index (EASI) ≥12
and ≤ 48 (0-72 scale). Following a run-in subjects were randomized to receive either oral 30
mg ZPL-3893787 once daily (od) or placebo od for 8 weeks (56 days).